An independent legal panel rejects allegations in shareholder lawsuits that Medtronic ran a scheme to promote off-label use of its controversial Infuse bone growth product. An independent panel tasked with evaluating lawsuits filed against Medtronic (NYSE:MDT) over its Infuse bone graft product is asking state and federal courts in Minnesota to dismiss the complaints after finding no evidence that the medical device giant “designed and executed a scheme to evade the FDA’s prohibition against off- label promotion in order to increase the sales of Infuse.”
Help employers find you! Check out all the jobs and post your resume.
